Abstract
Background
About 80% of prolactinomas respond to dopamine agonists (DA) with hormonal normalization and tumor shrinkage. Mechanisms of DA resistance include reduction of dopamine receptor subtype 2 (DRD2) expression, short and long isoform ratio and post-receptor mechanisms. It was suggested that polymorphisms in the gene encoding dopamine receptor subtype 2 gene (DRD2) could be associated with variable effectiveness of cabergoline (CAB).
Objective
To assess the influence of DRD2 polymorphisms in responsiveness of CAB treatment in patients with prolactinoma.
Study design and patients
Cross-sectional retrospective case–control study analyzing the frequency of five DRD2 polymorphisms in 148 patients with prolactinoma and 349 healthy subjects. The association of genetic variants and clinical characteristics with CAB responsiveness was performed in 118 patients (mean age at diagnosis 29 years; range 11–61 years) with hormonal evaluation. Patients with prolactin (PRL) normalization were considered as responders.
Results
No association in genotypes and allele proportions was found comparing patients and controls. On pharmacogenetic study, 118 patients on CAB were included and 20% were non-responders. No association was found between clinical characteristics (gender, age, PRL level and tumor size at diagnosis) and polymorphisms of DRD2 with CAB responsiveness. Otherwise, there was association between polymorphisms rs1076560 (allele A) and rs1800497 (allele T) and the presence of macroadenomas.
Conclusion
No correlation was found between DRD2 polymorphisms and CAB responsiveness in patients with prolactinoma. More data are necessary in order to assess the influence of DRD2 genoty** on DA treatment response.
Similar content being viewed by others
References
Hardy J (1973) Transphenoidal surgery of hypersecretiom pituitary tumors. In: Kohler PO, Ross GT (eds). Int Congr Ser 303. Amsterdam, pp 179–194
Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84(7):2518–2522
Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G et al (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574–3579
Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R et al (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85(6):2247–2252
Filopanti M, Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S et al (2008) Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogen J 8(5):357–363
Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160(5):747–752
Molitch ME (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8(1):43–52
Passos VQ, Fortes MA, Giannella-Neto D, Bronstein MD (2009) Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89(2):163–170
Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP et al (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69(3):500–509
Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D et al (1994) Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60(3):314–322
Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A (1996) Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol 8(10):737–746
Peverelli E, Mantovani G, Vitali E, Elli FM, Olgiati L, Ferrero S et al (2012) Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab 97(3):967–977
Zhang JP, Lencz T, Malhotra AK (2010) D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 167(7):763–772
Hirvonen M, Laakso A, Någren K, Rinne JO, Pohjalainen T, Hietala J (2004) C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 9(12):1060–1061
Hirvonen MM, Laakso A, Någren K, Rinne JO, Pohjalainen T, Hietala J (2009) C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 63(10):907–912
Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48(7):648–654
Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK et al (1997) D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7(6):479–484
Pohjalainen T, Rinne JO, Någren K, Lehikoinen P, Anttila K, Syvälahti EK et al (1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3(3):256–260
Jönsson EG, Nöthen MM, Grünhage F, Farde L, Nakashima Y, Prop** P et al (1999) Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4(3):290–296
Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R et al (2007) Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA. 104(51):20552–20557
Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J et al (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205–216
Hansen KA, Zhang Y, Colver R, Tho SP, Plouffe L, McDonough PG (2005) The dopamine receptor D2 genotype is associated with hyperprolactinemia. Fertility Sterility 84(3):711–718
Ilhan M, Kahraman OT, Turan S, Turgut S, Karaman O, Zeybek U et al (2015) Does DRD2 polymorphism influence the clinical characteristics of prolactinoma? Ann Endocrinol 76(5):614–619
Jönsson EG, Nöthen MM, Neidt H, Forslund K, Rylander G, Mattila-Evenden M et al (1999) Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr Res 40(1):31–36
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215
Heinze G (2006) A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med 25(24):4216–4226
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. Ser B (Methodological) 57(1):289–300
Moura RR, Coelho AV, Balbino VQ, Crovella S, Brandão LA (2015) Meta-analysis of Brazilian genetic admixture and comparison with other Latin America countries. Am J Hum Biol 27(5):674–680
Pena SD, Bastos-Rodrigues L, Pimenta JR, Bydlowski SP (2009) DNA tests probe the genomic ancestry of Brazilians. Braz J Med Biol Res 42(10):870–876
Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, FeS Kehdy et al (2011) The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS ONE 6(2):e17063
Schaid DJ, Jacobsen SJ (1999) Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions. Am J Epidemiol 149(8):706–711
Slatkin M (2008) Linkage disequilibrium–understanding the evolutionary past and map** the medical future. Nat Rev Genet 9(6):477–485
Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102–2107
Delgrange E, Vasiljevic A, Wierinckx A, François P, Jouanneau E, Raverot G et al (2015) Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172(6):791–801
Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD et al (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331
Delgrange E, Duprez T, Maiter D (2006) Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol 64(4):456–462
Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114(2):336–344
Ritchie T, Noble EP (2003) Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 28(1):73–82
Eisenstein SA, Bogdan R, Love-Gregory L, Corral-Frías NS, Koller JM, Black KJ, et al. (2016) Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status. Synapse 70(10):418–431
Bertolino A, Fazio L, Caforio G, Blasi G, Rampino A, Romano R et al (2009) Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 132(Pt 2):417–425
Peculis R, Balcere I, Rovite V, Megnis K, Valtere A, Stukens J et al (2016) Polymorphisms in MEN1 and DRD2 genes are associated with the occurrence and characteristics of pituitary adenomas. Eur J Endocrinol 175(2):145–153
Acknowledgements
This work was supported by institutional grant from CAPES (to C.B.F.B.); Grant 2011/19932-5 from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Federico Foundation (to A.G.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Bueno, C., Trarbach, E., Bronstein, M. et al. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment. Pituitary 20, 295–300 (2017). https://doi.org/10.1007/s11102-016-0776-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-016-0776-4